Speakers: John Sninsky, PhD, CSO-CIO, Superfluid Dx
Organizers:
Date: 2024-06-20
Time: 11:15-13:30 Pacific Time
Registration fee: Major Sponsor: $3000; Vendor Show: $695; Regular attendees: Free
Location: Crowne Plaza, Foster City, CA (San Francisco Bay Area)
Major Sponsor:
Vendor show vendors registered to date: (2)Agilent Technologies; HICOMP MicroTech Co. Ltd
Registration: http://www.PBSS.org
Registration deadline:2024-06-15  (it will close sooner if the seating cap is reached)

About the Topic

Seminar Synopsis: Identifying disease modifying therapies for Alzheimer’s Disease (AD) has proven extremely challenging. The amyloid cascade hypothesis has given way to the ATX (N) conceptual framework. Mild Cognitive Impairment is now recognized as a heterogenous unstable condition that is not a stage in an inexorable progression to AD. Also, we now have evidence that lifestyle interventions can delay progression separate from pharmacotherapies. As with other common complex diseases in the Precision Medicine Era, we need to appreciate that AD is likely a combination of multiple overlapping endotypes with clinical trials and patient management optimally informed by combinations of biomarkers. Through this seminar, the speaker will shed light on the current understanding about the causes of AD, the current state of art in AD  diagnostics and treatment, and the future directions of future precision diagnostics and therapeutics for AD.

John J Sninsky, PhD, is CSO-CIO for Superfluid Dx, an early-stage biotechnology company with a disease agnostic pioneering cell free mRNA platform that uses NGS and machine learning to develop classifiers for compelling unmet clinical needs. Superfluid Dx has prioritized Alzheimer’s Disease. John has a comprehensive and deep understanding of the development and application of pioneering molecular procedures and bioinformatics to the translation of research-grade biomarker assays into clinical-grade clinically adopted diagnostic tests as well as diagnostic tests paired with pharmacotherapies.  John is the author of more than 115 scientific papers including advanced methods in molecular biology and next generation sequencing. He spent 30 years in senior management at companies that ranged from small to enterprise CLIA-CAP laboratories and small to enterprise in vitro diagnostic companies that required FDA clearance and approval for commercialization of kits. He lectures at and advises commercial translation efforts at Stanford University (SPARK) and University of California, San Francisco (CATALYST). John is a Visiting Professor in the Division Infectious Diseases and Vaccinology in School of Public Health at UC Berkeley. He mentors Biomedical Data Science projects for the Data Mine at Purdue University. Through this seminar, the speaker will shed light on the current understanding about the causes of AD, the current state of art in AD diagnostics and treatment, and the future directions of future precision diagnostics and therapeutics for AD.